Skip to main content
. Author manuscript; available in PMC: 2020 Sep 21.
Published in final edited form as: Lab Invest. 2020 Mar 6;100(10):1356–1366. doi: 10.1038/s41374-020-0413-8

Figure 3: The OV signature can be used to stratify individual clinical variables.

Figure 3:

a. Box plot of PSs in samples from early (1 and 2) and late stages (3 and 4), Wilcoxon Rank-Sum Test. b. Box plot of PSs comparing samples with non-recurrent and recurrent events, Wilcoxon Rank-Sum Test. c. Box plot of PSs in samples classified as optimal (Opt) and suboptimal (Sub), Wilcoxon Rank-Sum Test. d. Kaplan-Meier plot depicting survival probability of optimal and suboptimal patients stratified by high-PS or low-PS (based on median PS), Log-rank Test. e. Box plot of PS in differentiated (Dif), Immune (Imm), Mesenchymal (Mes), and Proliferative (Pro) OV subtypes, Wilcoxon Rank-Sum Test. Kaplan-Meier plots depicting survival probability of PS-high and PS-low samples in f. Differentiated, g. Immunoreactive, h. Mesenchymal, and i. Proliferative OV subtypes, Log-rank Test.